Detailed price information for Ventyx Biosciences Inc (VTYX-Q) from The Globe and Mail including charting and trades.

Ventyx Biosciences (NASDAQ:VTYX) slid 10% on Tuesday after the biotech firm said it will postpone the interim analysis from ...

Investing.com -- Ventyx Biosciences (NASDAQ:VTYX) stock fell 10% after the clinical-stage biopharmaceutical company announced it would delay the release of interim analysis data from its Phase 2 ...

Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and the ...

RBC upgrades Neumora, citing strong early NLRP3 obesity data and growing pipeline momentum ahead of key 2026 readouts.

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated ...

Every investor in Ventyx Biosciences, Inc. (NASDAQ:VTYX) should be aware of the most powerful shareholder groups. With 57% stake, institutions possess the maximum shares in the company. In other words ...

Ventyx Biosciences Inc. (NASDAQ:VTYX) is among the hottest SMID-cap stocks so far in 2025. On November 7, TheFly reported that Canaccord Genuity modestly increased its price target on the company’s ...

Shares of Ventyx Biosciences VTYX have skyrocketed 156% in the past month. The massive surge in the stock price was primarily driven by the success of the company’s mid-stage study evaluating its ...

A webcast of the event will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website after the conclusion of ...